series-c-plus
Stage
2018
Founded
2
Investors
About
OncoHost develops the PROphet platform, a plasma- or serum-based proteomic test that uses bioinformatic pattern recognition and AI to generate a personalized score predicting likely benefit from PD-1/PD-L1 inhibitor therapies to inform oncology treatment decisions.
Explore OncoHost's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.